Apple Inc. v. Zipit Wireless, Inc., Appeal No. 2021-1760 (Fed. Cir. Apr. 18, 2022) -
In its only precedential patent case this week, the Federal Circuit addressed the extent to which a party exposes itself to personal...more
Niazi Licensing Corporation v. St. Jude Medical SC, Inc., Appeal No. 2021-1864 (Fed. Cir. Apr. 11, 2022) -
The Federal Circuit’s only precedential patent decision this week comes on appeal from a district court decision...more
Littelfuse, Inc. v. Mersen USA EP Corp., Appeal No. 2021-2013 (Fed. Cir. Apr. 4, 2022) -
Our Case of the Week focuses on the issue of claim construction, and, more specifically, the doctrine of claim differentiation....more
In re: Volkswagen Group of America, Inc. and In re: Hyundai Motor America, Appeal Nos. 2022-108, -109 (Fed. Cir. Mar. 9, 2022) -
In the most recent of multiple mandamus rulings issued by the Federal Circuit in relation to...more
3/15/2022
/ Appeals ,
Claim Construction ,
Dismissals ,
Improper Venue ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Vacated ,
Venue ,
Writ of Mandamus ,
Written Descriptions
DBN Holding, Inc. v. International Trade Commission, Appeal No. 2020-2342 (Fed. Cir. Mar. 1, 2022) -
The Federal Circuit issued only one precedential decision this week relating to a patent case. On this appeal—the fourth...more
Alarm.com Inc. v. Hirshfeld, Appeal No. 2020-2102 (Fed. Cir. Feb. 24, 2022)-
In an appeal from the U.S. District Court for the Eastern District of Virginia, the Federal Circuit addressed whether the ex parte reexamination...more
3/1/2022
/ Appeals ,
Coronavirus/COVID-19 ,
Estoppel ,
Ex Partes Reexamination ,
Inter Partes Review (IPR) Proceeding ,
Judicial Review ,
Oral Argument ,
Patent Litigation ,
Patents ,
Sanctions ,
USPTO
Adapt Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc., Appeal No. 2020-2106 (Fed. Cir. Feb. 10, 2022) -
In our Case of the Week, the Court of Appeals for the Federal Circuit, in both the majority opinion and...more
2/15/2022
/ Appeals ,
En Banc Review ,
Inter Partes Review (IPR) Proceeding ,
IP License ,
Motion To Seal ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Preliminary Injunctions ,
Prior Art ,
Remand ,
Third-Party ,
Vacated
The Federal Circuit issued numerous precedential opinions last week, two of which answered long simmering questions about inter partes reviews (IPRs). Below we discuss a case addressing whether admissions of prior art in the...more
2/8/2022
/ Abstract Ideas ,
Appeals ,
Claim Construction ,
Damages ,
Estoppel ,
Inter Partes Review (IPR) Proceeding ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Preliminary Injunctions ,
Prior Art ,
Remand ,
Settlement Agreements
Nature Simulation Systems Inc. v. Autodesk, Inc., Appeal No. 2020-2257 (Fed. Cir. Jan. 27, 2022) -
In its only precedential patent decision this week, the Court of Appeals for the Federal Circuit corrected what it...more
Evolusion Concepts, Inc. v. HOC Events Inc., Appeal No. 2021-1963 (Fed. Cir. Jan. 14, 2022)
In its only precedential patent case this week, the Federal Circuit disposed of an appeal, holding that the district court’s...more
Intel Corp. v. Qualcomm Inc., Appeal Nos. 2020-1828, -1867 (Fed. Cir. Dec. 28, 2021) -
The Federal Circuit issued two precedential decisions this week—both arising from IPRs filed by Intel against patents owned by...more
1/4/2022
/ Appeals ,
Claim Construction ,
Constitutional Challenges ,
Inter Partes Review (IPR) Proceeding ,
Means-Plus-Function ,
Obviousness ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Prior Art ,
Standing
AstraZeneca AB v. Mylan Pharmaceuticals Inc., Appeal No. 2021-1729 (Fed. Cir. Dec. 8, 2021) -
Our Case of the Week again focuses on numerical values in claims. Last week we addressed a case involving whether there was...more
Biogen International GMBH v. Mylan Pharmaceuticals Inc., Appeal No. 2020-1933 (Fed. Cir. Nov. 30, 2021) -
For the second time in two weeks, our Case of the Week focuses on the written description requirement, in...more
Indivior UK Ltd. v. Dr. Reddy’s Laboratories S.A., Appeal Nos. 2020-2073, -2142 (Fed. Cir. Nov. 24, 2021) -
Our Case of the Week this week focuses on the written description requirement when the patent claims a range. The...more
University of Strathclyde v. Clear-Vu Lighting LLC, Appeal No. 2021-2243 (Fed. Cir. Nov. 4, 2021) -
In this week’s Case of the Week, the Federal Circuit reversed an inter partes review decision finding claims directed to...more
11/9/2021
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Dismissals ,
Improper Venue ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Prior Art
Mobility Workx, LLC v. Unified Patents, LLC, Appeal No. 2020-1441 (Fed. Cir. Oct. 13, 2021) -
In this week’s Case of the Week, a panel of the Court of Appeals for the Federal Circuit considered, and rejected, new...more
10/19/2021
/ America Invents Act ,
Appeals ,
Attorney's Fees ,
Claim Construction ,
Constitutional Challenges ,
Noninfringement ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Remand ,
Section 145 ,
Section 285 ,
Summary Judgment ,
USPTO ,
Vacated
Kannuu Pty Ltd. v. Samsung Electronics Co., Appeal No. 2021-1638 (Fed. Cir. Oct. 7, 2021) -
In our Case of the Week, the Federal Circuit addressed whether a forum selection clause in an NDA may prohibit a party from...more
10/12/2021
/ Appeals ,
Claim Construction ,
Design Patent ,
Inter Partes Review (IPR) Proceeding ,
Non-Disclosure Agreement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent Validity ,
Patents ,
Section 101 ,
Subject Matter Jurisdiction
In re: Vivint, Inc., Appeal No. 2020-1992 (Fed. Cir. Sept. 29, 2021) -
In an appeal from the United States Patent Trial and Appeal Board, the Federal Circuit addressed whether a party may challenge the validity of an...more
In re: Juniper Networks, Inc., Appeal No. 2021-160 (Fed. Cir. Sept. 24, 2021)-
In this week’s Case of the Week, the Federal Circuit issued its fifth writ of mandamus this year ordering transfer of a patent case out of the...more
Omega Patents, LLC, v. CalAmp Corp., Appeal Nos. 2020-1793, -1794, (Fed. Cir. Sept. 14, 2021) -
In its only precedential patent case this week, the Federal Circuit sent a case back for a third trial on the issue of...more
Belcher Pharmaceuticals, LLC v. Hospira, Inc., Appeal No. 2020-1799 (Fed. Cir. Sept. 1, 2021) -
In an appeal from the United States District Court for the District of Delaware, the Federal Circuit affirmed the district...more
9/8/2021
/ Appeals ,
Failure To Disclose ,
Food and Drug Administration (FDA) ,
Inequitable Conduct ,
Inventions ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patent Notice ,
Patents ,
Pharmaceutical Patents ,
Remand ,
Trademarks ,
USPTO
MLC Intellectual Property, LLC v. Micron Technology, Inc., Appeal No. 2020-1413 (Fed. Cir. Aug. 26, 2021) -
For those interested in an important Section 112 written description case, we recommend reading the Juno...more
8/31/2021
/ Appeals ,
Apportionment ,
Damages ,
Discovery ,
Expert Testimony ,
Failure To Disclose ,
Inter Partes Review (IPR) Proceeding ,
Inventions ,
Inventors ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Section 101
Teva Pharms. Int’l GmbH v. Eli Lilly and Co., Appeal Nos. 2020-1747, -1748, -1750 (Fed. Cir. Aug. 16, 2021) -
Eli Lilly and Co. v. Teva Pharms. Int’l GmbH, Appeal Nos. 2020-1876, -1877, -1878 (Fed. Cir. Aug. 16, 2021)...more
PersonalWeb Technologies LLC v. Google LLC, Appeal Nos. 2020-1543, -1553, -1554 (Fed. Cir. Aug. 12, 2021)
In this week’s Case of the Week, the Federal Circuit affirmed a district court’s judgment on the pleadings that...more
Our Case of the Week this week is a re-write of our Case of the Week on October 5, 2020. The case involves a drug that could be used for multiple therapeutic purposes. A patent covered use of the product for a specific...more
8/10/2021
/ Appeals ,
Damages ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Hatch-Waxman ,
Improper Venue ,
Inventions ,
Labeling ,
Liability ,
Motion to Dismiss ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Subject Matter Jurisdiction